Core Insights - INNOVATE Corp. reported strong financial results for Q4 and full year 2025, with a consolidated revenue increase of 61.7% year-over-year for Q4 and 12.5% for the full year, driven primarily by the Infrastructure segment [2][3][7]. Financial Performance - Q4 2025 revenue reached $382.7 million, up from $236.6 million in Q4 2024, while full year revenue was $1,246.0 million compared to $1,107.1 million in 2024 [2][7]. - The net loss attributable to common stockholders decreased to $7.8 million in Q4 2025 from $16.9 million in Q4 2024, and for the full year, the net loss was $64.0 million compared to $35.8 million in 2024 [2][10]. - Basic and diluted loss per share improved to $(0.58) in Q4 2025 from $(1.29) in Q4 2024, and for the full year, it was $(4.84) compared to $(3.08) in 2024 [2][10]. Segment Performance - The Infrastructure segment, led by DBM Global, reported Q4 revenue of $373.9 million, a 65.7% increase from $225.7 million in the prior year quarter, with a net income of $10.6 million [4][10]. - Life Sciences segment revenue for Q4 was $3.1 million, down 24.4% from $4.1 million in the prior year, but full year revenue increased by 27.6% to $12.5 million [4][10]. - Spectrum segment revenue for Q4 was $5.7 million, down from $6.8 million in the prior year, impacted by customer terminations [4][10]. Strategic Developments - INNOVATE's Infrastructure segment has a backlog of $1.8 billion, indicating strong future revenue visibility [3][9]. - MediBeacon received FDA approval for the next generation MediBeacon TGFR System, and R2 secured a minimum purchase agreement for 600 systems in China over three years [3][9]. - Spectrum is expected to benefit from favorable FCC rulings and new network launches, with significant opportunities for expansion in the coming year [3][9]. Adjusted EBITDA - Total Adjusted EBITDA for Q4 2025 was $24.5 million, up from $15.0 million in Q4 2024, primarily driven by the Infrastructure segment [13][14]. - The Infrastructure segment's Adjusted EBITDA increased to $28.0 million from $17.4 million in the prior year quarter [13][14]. Balance Sheet - As of December 31, 2025, INNOVATE had cash and cash equivalents of $112.1 million, up from $48.8 million a year earlier [17][33]. - Total assets increased to $950.1 million from $891.1 million in the previous year, while total liabilities rose to $1,165.4 million from $1,034.8 million [33].

Core Viewpoint - MediBeacon Inc., in which INNOVATE Corp. holds a 44.7% equity interest, has received FDA approval for its next-generation TGFR System, which includes the TGFR Reusable Sensor, enhancing kidney function assessment technology [1][7]. Group 1: Product Details - The TGFR System allows for kidney function assessment at the point of care by measuring the clearance rate of Lumitrace (relmapirazin), a non-radioactive, non-iodinated fluorescent GFR agent [2]. - The TGFR Reusable Sensor is designed for patient comfort, ease of application, and reusability, reducing costs compared to the previously approved single-use TGFR Sensor [3]. - The TGFR System records Lumitrace fluorescence intensity transdermally at a rate of 2.5 readings per second, providing real-time data on kidney function [12]. Group 2: Clinical Validation and Research - The TGFR System was featured in a lead peer-reviewed article in the Journal of the American Society of Nephrology, highlighting its application across various levels of kidney function and skin colors [4]. - MediBeacon has a strong research background with over 700 peer-reviewed publications and conference abstracts utilizing the transdermal GFR methodology [5]. Group 3: Market Strategy and Future Plans - MediBeacon plans to offer early access to the TGFR System at leading academic medical centers in the U.S. and China, with initial sales expected to begin in the first quarter of 2026 [5][7]. - The company aims to integrate transdermal GFR technology into ongoing heart failure studies, emphasizing its potential to improve patient monitoring and accuracy in kidney function assessment [6]. Group 4: Company Overview - INNOVATE Corp. is focused on key areas of the new economy, including Infrastructure, Life Sciences, and Spectrum, employing approximately 3,100 people across its subsidiaries [8]. - MediBeacon specializes in fluorescent tracer agents and transdermal detection technology, holding over 60 granted U.S. patents and more than 245 patents worldwide [9].